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Abstract
Background: CNS injury including stroke, infection, and tumor growth lead to astrogliosis, a process that involves
upregulation of glial fibrillary acidic protein (GFAP) in astrocytes. However, the kinetics of astrogliosis that is related
to these insults (i.e. tumor) is largely unknown.
Results: Using transgenic mice expressing firefly luciferase under the regulation of the GFAP promoter (GFAP-luc),
we developed a model system to monitor astrogliosis upon tumor growth in a rapid, non-invasive manner. A
biphasic induction of astrogliosis was observed in our xenograft model in which an early phase of activation of
GFAP was associated with inflammatory response followed by a secondary, long-term upregulation of GFAP. These
animals reveal GFAP activation with kinetics that is in parallel with tumor growth. Furthermore, a strong correlation
between astrogliosis and tumor size was observed.
Conclusions: Our results suggest that non-invasive, quantitative bioluminescent imaging using GFAP-luc reporter
animal is a useful tool to monitor temporal-spatial kinetics of host-mediated astrogliosis that is associated with
glioma and metastatic brain tumor growth.
Background
The tumor microenvironment is a dynamic niche for
tissue remodeling because of its production of tumor
cell- and host stromal cell-derived growth factors, cyto-
kines and matrix proteins. Historically, the study of such
host-stromal interactions has generally relied on classical
histological methods such as immunohistochemistry, in
situ hybridization or biochemical techniques such as
immunoblotting and enzyme assays. Unfortunately, the
analytical power of these techniques is limited by the
ability of reagents to distinguish between tumor and
host compartments and by the need for terminal harvest
of tissues for analysis. For example, in malignant glio-
mas, tumor cells co-opt the functions of the surround-
ing brain to support their growth and invasion.
However, gliomas fail to completely compromise an
otherwise tight blood brain barrier of normal vessels,
based on the wide range of drugs and small molecules
that fail to cross the BBB and target brain tumors [1].
GFAP expression has been widely used as a marker
for astrogliosis and the host response to injury [2-4] and
its analysis has generally relied on immunohistochemis-
try rather than quantification. Recently, however, biolu-
minescent imaging of GFAP activity using transgenic
GFAP-luc mice has been reported to measure astroglio-
sis in animal models of kainic lesions [5], prion infection
[6], ischemic injury [7], and experimental autoimmune
encephalomyelitis (EAE)[8], but has not been described
in a tumor model. In this study, we used immunodefi-
cient (i.e., Rag2
-/-)t r a n s g e n i cG F A P - l u cm i c e[ 5 ]t o
grow orthotopic brain tumors and to monitor the co-
activation of the GFAP promoter with tumor develop-
ment. GFAP promoter activation was used as a surro-
gate marker for host compartment astrogliosis to assess
tumor progression. Here we show that these GFAP-luc;
Rag2
-/- mice injected with malignant glioma cells can be
used to monitor and quantify tumor-induced astrogliosis
response of the host. Analysis of the serial imaging sup-
ports a model in which intracranial tumor injection
induces an early GFAP response, which is likely a conse-
quence of the local wounding of the stereotactic injec-
tion. This early response resolves and is followed by a
secondary astrogliosis response correlating with tumor
progression both in terms of kinetics and localization. * Correspondence: beliceiri@ucsd.edu
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Immunohistochemical analysis of GFAP activity in tumor-
bearing brain
To determine the effect of orthotopic tumor xenografts
on GFAP activity we subjected immunodeficient Rag2
-/-
mice (i.e. T and B cells defective) [9] to stereotactic
injection with DBTRG glioma cells as described in the
Methods. These glioma cells have been previously
shown to be highly invasive with infiltrative, satellite
t u m o r sd i s t a n tf r o mt h ep r imary tumor [10-12]. Both
primary and infiltrative tumors induce specific remodel-
ing of the surrounding microenvironment, which has
been analyzed by immunohistochemical analyses of cell-
type specific markers, for example, GFAP, to detect
remodeling and activation of the astrocytes [10]. In
agreement with previous observations from our labora-
tory and others [10,13-16], GFAP activity was highly
upregulated at the tumor margin and adjacent tissue
forming a glial scar, whereas a decrease in GFAP immu-
noreactivity was observed in the tumor core (Figure 1).
Although GFAP is generally detected in primary glial
brain tumors, its expression is often lost in cell lines
established from malignant gliomas such as DBTRG
cells [17,18]. Thus, scattered GFAP immunoreactivity
inside the tumor was likely from infiltrating astrocytes
from the host rather than from the human DBTRG
tumor cells themselves. Previous observations using a
different astrocyte marker, Aldh1L1 (a marker for proto-
plasmic astrocytes) [19] demonstrate a similar immunos-
taining pattern with GFAP (i.e. upregulation at the
tumor margin, but decrease in the tumor core). How-
ever, aquaporin 4 (AQ4, a marker for astrocytic endfeet)
immunoreactivity was upregulated in the tumor core
and, moreover, contact with endothelial cells was lost
inside tumors [10], indicating that distinct subsets of
astrocytes react differently upon glioma growth.
While these immunohistochemical techniques are use-
ful for understanding tumor-induced host remodeling at
a cellular level, they rely on the availability and valida-
tion of species-specific antibodies to distinguish tumor
vs host compartment responses. To develop a rapid,
quantitative model to better understand the temporal
progression of astrocytic gliosis upon tumor growth, we
used GFAP-luc reporter animals for a non-invasive
detection of tumor-induced astrogliosis.
Non-invasive imaging analyses of glioma-induced GFAP
activation
To determine the effect of orthotopic tumor growth on
GFAP promoter-mediated luciferase activity, we back-
crossed GFAP-luc mice to an immunodeficient Rag2
-/-
background. We then injected lentiviral-transduced,
DBTRG cells expressing red fluorescent protein
(DBTRG-RFP) into the brains of 10 week-old GFAP-
luc; Rag2
-/- mice by stereotactic injection. Intracranial
injections of an equal volume of PBS were used to
control for injury induced by the injection itself. As
reported earlier [6,20], intracranial injections of PBS
alone induced a transient injury response, which was
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Figure 1 Using standard immunohistochemical technique to
assess GFAP activity in tumor-bearing brain. (A) DBTRG glioma
cells were introduced into mice by stereotactic injection. Following
three weeks incubation, brains were harvested and sections were
made to measure GFAP activity in tumor bearing vs. contralateral
brain by immunohistochemistry. Sections were counterstained with
DAPI and tumor area was defined by dense nuclei staining of the
tumor cells (dotted line). An example of exposure-matched images of
tumor-bearing brain (right) and its contralateral hemisphere (left) is
shown. Note the upregulated GFAP activity at the tumor margin
(right). Scale bar = 1 mm. (B) Fluorescently labeled DBTRG-Zsgreen
glioma cells (green) were introduced into mice by stereotactic
injection. Following three weeks incubation, brains were harvested
and sections were made to measure GFAP activity (red) by
immunohistochemistry. A representative image of upregulated GFAP
immunoreactivity at the tumor margin compared to the tumor core
is shown. Scale bar = 100 μm. (C) GFAP immunoreactivity in tumor
margin (defined by fluorescent activity of the tumor cells), tumor
core vs. normal area (contralateral) was quantified by measuring the
fluorescent intensity of images in panel (B). Results are shown as an
average of three mice. At least three independent areas were
quantified from each mouse. P < 0.05, Wilcoxon rank sum test, two-
sided. Error bar represents standard deviation.
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Page 2 of 7detected at day 3 but diminished by week two (Figure
2). Tumor cells induced a biphasic host astrogliosis
response in which tumor cells initially induced GFAP-
luc levels that was higher than control followed by a
reduction to background by day 7. However, further
tumor growth after three and four weeks led to sec-
ond, larger, sustained and statistically significant five-
fold increase of GFAP activity over PBS controls (Fig-
ure 2).
Non-invasive imaging analyses of metastatic brain tumor-
induced GFAP activation
Metastatic brain tumors also induce reactive astrogliosis
in the brain [21,22], therefore, we tested whether cancer
cells of non-CNS origin activate GFAP in our model.
Following stereotactic injection of MDA-MB231 human
breast cancer cells, we observed similar results (i.e.
biphasic activation of luciferase upon tumor implanta-
tion)(Figure 3). These data indicate that the GFAP-luc;
Rag2
-/- mice are useful tools to monitor reactive tumor-
induced astrogliosis of the host compartment non-
invasively.
Real time monitoring of spatial distribution of host-
mediated astrogliosis
To understand the spatial distribution of GFAP-activa-
tion relative to the tumor in real-time, we generated a
three-dimensional reconstruction of astrogliosis in
tumor-bearing mice using Living Image 4.0 (Caliper Life
Science). GFAP-luc; Rag2
-/- mice were injected with
RFP-labeled DBTRG glioma cells and incubated for four
weeks. At four week, the bioluminescence signals and
fluorescent signals were collected and analyzed. We
observed a localized tumor mass in the cortex, while
GFAP activity was upregulated more broadly in the
areas surrounding the tumor (Figure 4). In agreement
with the immunohistochemical data (Figure 1), there
was not a complete overlap between the tumor area and
GFAP activity suggesting that the GFAP response in the
luciferase reporter extends beyond the immediate tumor
margin (Figure 4 and Additional file 1).
GFAP activation correlates with tumor size
To determine whether astrogliosis was restricted to the
tumor region or a global astrocyte response was generated
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Figure 2 Non-invasive imaging of glioma-induced GFAP
activation. (A) GFAP-luc mice were injected with RFP-labeled
DBTRG human glioma cells (Tumor) or PBS (Control). GFAP activity
was monitored for up to four weeks. An exposure-matched,
representative non-invasive image of each time point is shown. (B)
Quantitative measurement of panel (A). Reactive gliosis was
observed three days post-implantation in both tumor and PBS
injected animals. Upon tumor growth, GFAP activity increased after
14 day of implantation in animals injected with tumor cells, while
only background GFAP activity was observed in animals without
tumor. N = 6-7 for each group, Wilcoxon rank sum test, two-sided, *
P < 0.01 at day 4, 21 and 28, error bar represents standard
deviation.
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Figure 3 Non-invasive imaging of metastatic brain tumor-
induced GFAP activation. (A) GFAP-luc mice were injected with
MDA-MB-231 breast tumor cells (Tumor) or PBS (Control). GFAP
activity was monitored for up to four weeks. An exposure-matched,
representative non-invasive image of each time point is shown. (B)
Quantitative measurement of panel (A). Reactive gliosis was
observed three days post-implantation in both tumor and PBS
injected animals. Upon tumor growth, GFAP activity increased after
14 day of implantation in animals injected with tumor cells, while
only background GFAP activity was observed in animals without
tumor. N = 8-9 for each group, Wilcoxon rank sum test, two-sided, *
P < 0.05 at day 3,7, and 28, error bar represents standard deviation.
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Page 3 of 7as a consequence of tumor growth, we monitored lucifer-
ase activity in brain sections. Following a four-week incu-
bation of glioma in vivo, the brain was harvested and 1
mm brain sections were prepared. Consistent with the
immunohistochemical data (Figure 1), reactive astrogliosis
was observed only in tumor-bearing sections and sections
adjacent to tumors (Figure 5A). Furthermore, we observed
a statistically significant correlation between tumor size
(i.e. fluorescent intensity of RFP-labeled glioma cells)
and astrogliosis (i.e. GFAP-mediated luciferase activity)
(Figure 5B, p < 0.01).
GFAP immunostaining (Figure 1) and our biolumines-
cent reporter model (Figure 4 and 5) both indicated that
tumor induced-GFAP activity was mainly observed in
the microenvironment of the tumor. On the other hand,
GFAP activity in the contralateral hemisphere (adjacent
to tumor-bearing hemisphere) was very low and close to
the baseline activity of GFAP observed in control brain
w i t hn oi n j u r y .A l t h o u g hw eh a v ef o u n das i g n i f i c a n t
correlation between the tumor size and astrogliosis in
the tumor microenvironment, we did not observe a sig-
nificant change of global GFAP activity (i.e. non-tumor
bearing brain slabs of tumor-bearing animals) based on
tumor size.
In mouse EAE and prion infection models there is a
direct correlation between the amount of GFAP-
mediated luciferase activity and the intensity of the
insult [6,8]. Yet, in the mouse model of ischemic injury
in the CNS, a correlation between the GFAP activity
and infarct size was observed only in the male mice [7].
Although not a focus of these studies, we did not
observe any differences in the GFAP activity upon
tumor growth between male and female animals. How-
ever, other tools to monitor astrogliosis maybe useful to
assess gender differences in future studies.
We established that transgenic GFAP-luc reporter
mice are useful to study the interaction of the tumor
growth and astrogliosis. The non-invasive nature of this
B
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Figure 4 Spatial distribution of host-mediated astrogliosis.( A )
3D images using diffuse tomographic reconstruction algorithms for
fluorescence (RFP-labeled tumor) or bioluminescent sources (GFAP
activity, luciferase) were created with tumor-bearing GFAP-luc mice
after a four-week incubation. Representative coronal, sagittal, and
transaxial images from the center of the tumor is shown. Note the
upregulation of GFAP activity adjacent to the tumor (merged
image). (N = 3). (B) 3D reconstruction of fluorescent or
bioluminescent sources in the whole animal is shown. While
fluorescent signal from tumor was localized, GFAP activity was
upregulated at the tumor periphery. Merged images from dorsal,
left side, ventral and right side is shown. A representative image of
three independent experiments is shown.
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Figure 5 GFAP activation correlates with tumor location and
tumor size. (A) GFAP-luc mice were injected with RFP-labeled
human glioma cells, incubated for 4 weeks and six 1 mm coronal
brain sections (numbered 1-6, anterior to posterior) were made for
each animal. Tumor (red, left panel) and tumor-induced GFAP
activation (luciferase, right panel) were localized in the same
sections. A representative image of brain sections is shown. (B)
Tumor burden (measured by its fluorescent intensity) and GFAP
activation (measured by luciferase activity) from four tumor-bearing
animals (at least five sections from each animal) were quantified.
GFAP activity correlates with tumor size. Kendall’s rank correlation
test, two-sided, coefficient index τ = 0.54, P < 0.01.
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Page 4 of 7model can be used for the dynamic assessment of astro-
gliosis during the course of tumor treatment after the
delivery of chemotherapeutic drugs or early detection of
a recurring tumor. Transgenic reporter models such as
GFAP-luc provide insights into the molecular physiology
of the tumor microenvironment which maybe useful for
drug discovery or screening [23] and evaluating other
transgenic models for host compartment specific
response to glioma growth and invasion.
Conclusions
Together, these results indicate that GFAP activity can
be used as a surrogate marker for tumor-induced astro-
gliosis. Unlike the traditional methods to monitor astro-
gliosis, these reporter mice can be utilized for rapid,
quantitative, and dynamic assessments of the tumor-
host interaction.
Methods
Animals
GFAP-luc transgenic mice (FVB/N-Tg(Gfap-luc)-Xen)
expressing the firefly luciferase gene under the control of
12 kb murine GFAP promoter were obtained from Cali-
per Life Sciences (Hopkinton, MA). These animals were
backcrossed into a Rag2
-/- immunodeficient background
(i.e. T and B cell deficient) for at least five generations to
avoid rejections of the xenograft [9]. Mice were geno-
typed by quantitative PCR using primers specific for the
luciferase transgene (Transnetyx Inc). Mice that did not
show baseline GFAP activity (measured by luciferase
activity before intracranial injection) were excluded from
the study. All animal husbandry and handling procedures
were approved by the University of California San Diego
Institutional Animal Care and Use Committee.
Tumor cells
Early passages of patient-derived human glioma cells,
D B T R G( ak i n dg i f tf r o mD r .C .K r u s e )[ 1 8 ]w e r eu s e d
in xenograft studies. These DBTRG cells were trans-
duced with lentivirus expressing red fluorescent protein
(DBTRG-RFP) or Zsgreen (DBTRG-Zsgreen) as
described earlier [10,12] to enable their identification
from normal CNS parenchyma. MDA-MB-231 breast
cancer cells were obtained from ATCC. All cells were
maintained in Dulbecco’s modified Eagle’s minimum
essential medium supplemented with 10% fetal bovine
serum, penicillin, streptomycin, nonessential amino
acids, and glutamine in a humidified atmosphere con-
taining 5% CO2 at 37°C.
Intracranial stereotactic injections
10 week-old mice were immobilized in a rodent stereo-
tactic frame, an incision made in the skin, and a burr
hole made in the skull. One million tumor cells
resuspended in 5 μl of PBS were injected at a rate of 1-
2 μl/minute using a Hamilton microsyringe (Hamilton,
Reno, NV) mounted on a stereotactic frame (Kopf Instru-
ments, Tujunga, CA) using coordinates of 1 mm lateral
and 2 mm posterior to the bregma and 2 mm below the
dura. The incision was closed with sterile sutures. Equal
volume of PBS (5 μl) was used as controls.
Quantification of bioluminescent imaging in vivo
Astrogliosis was monitored before (i.e. pre-operation) and
following of incubation of 3, 7, 14, 21 and 28 days post-
injection for tumor growth. Fur was removed from mice
with electric clippers and Nair (Church & Dwight Co.,
Inc., Princeton, NJ) before imaging at each time point. Bio-
luminescent signals were assessed 10 minutes after inter-
peritoneal D-luciferin injection (150 μl of 15 mg/ml stock)
using a cooled charge-coupled device (CCD) camera
(Spectrum; Caliper Life Sciences, Hopkinton, MA) capable
of in vivo imaging (using settings of exposure time 2-10
sec, large binning, F/Stop = 1). GFAP activity was moni-
tored by quantification of light emission from a region of
interest (ROI) at each time point (Unit = radiance). Biolu-
minescent signal from the ear represents basal level of
GFAP activity and were excluded from the ROI. Images
were analyzed using Living Image software version 4.0
(Caliper Life Sciences, Hopkinton, MA).
3D reconstruction of bioluminescent and fluorescent
signals
Gray-scale photographs and structured-light images
were collected to generate a 3D reconstruction of the
surface of the mice. 3D images were created using dif-
fuse tomographic reconstruction algorithms for fluores-
cence (Fluorescent Imaging Tomography, FLIT) or
bioluminescent sources (Diffused Luminescent Imaging
Tomography, DLIT) with Living Image software version
4.0. Bioluminescent signals were assessed 10 minutes
after D-luciferin injection (at the steady-state of luciferin
kinetic profile).
Immunohistochemistry
Three weeks after implantation, the animals were per-
fused with heparin/saline by intracardiac injection, the
brains harvested and cryoembedded in O.C.T. medium
(Miles Inc, Kankakee, IL). Standard immunohistochem-
istry was performed on cryosections (10 μm) of tumor
samples using the mouse monoclonal anti-GFAP
(C9205, Sigma, St.Louis, MO, 1:200) and Alexa-fluor-
conjugated secondary antibodies (Invitrogen, Carlsbad,
CA, 1:200). All sections were counterstained with
0.5 μg/ml DAPI (Sigma, St.Louis, MO) and tumor area
defined either by the typical dense nuclei staining of the
tumor (Figure 1A) or fluorescent activity of the tumor
cells (Figure 1B). Immunostaining of tissue sections
Lee et al. BMC Neuroscience 2011, 12:9
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Page 5 of 7were imaged with an Olympus Fluoview 1000 (ASW 1.7
b) laser scanning confocal microscope equipped with
2x/0.08 N.A., 10x/0.4N.A. and 20x/0.7N.A. dry-objective
lenses on a BX61 microscope (Olympus, Center Valley,
PA). GFAP immunoreactivity was quantified by defining
a region of interest (ROI) and by measuring the total
fluorescent units in the ROI in exposure-matched
images using Olympus Fluoview (ASW1.7 b) software.
Ex vivo analyses
Four weeks after tumor implantation, tumor-bearing
brain was harvested and 1 mm thick brain sections were
made. Tumor burden (measured by fluorescence of
RFP-labeled tumor cells) and astrogliosis (measured by
bioluminescence of GFAP-luc reporter) was quantitated
with a deep-cooled CCD imaging system equipped with
appropriate fluorescence filter cubes with background
subtraction. Images were analyzed using Living Image
software version 3.1.
Statistical analyses
All statistical analyses were performed using Mstat soft-
ware (version 5.10; N. Drinkwater, McArdle Laboratory
for Cancer Research, School of Medicine and Public
Health, University of Wisconsin, which is available for
downloading at http://www.mcardle.wisc.edu/mstat/).
Additional material
Additional file 1: Spatial distribution of host-mediated astrogliosis.
A movie of 3D reconstruction of fluorescent (RFP-labeled tumor) and
bioluminescent sources (GFAP activity, luciferase) in tumor-bearing GFAP-
luc mice after a four-week incubation is shown.
List of abbreviations
BBB: blood-brain barrier; CCD: charge-coupled device; CNS: central nervous
system; EAE: experimental autoimmune encephalomyelitis; GFAP: glial
fibrillary acidic protein.
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